Express delivery and free returns within 21 days

Thursday, July 7, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

4705 517227

Sample Post Title!

Sample Post Subtitle!

post content center img

Morbi libero lectus, laoreet elementum viverra vitae, sodales sit amet nisi. Vivamus dolor ipsum, ultrices in accumsan nec, viverra in nulla.

post content left img

Donec ligula sem, dignissim quis purus a, ultricies lacinia lectus. Aenean scelerisque, justo ac varius viverra, nisl arcu accumsan elit, quis laoreet metus ipsum vitae sem. Phasellus luctus imperdiet.

Donec tortor ipsum

Pharetra ac malesuada in, sagittis ac nibh. Praesent mattis ullamcorper metus, imperdiet convallis eros bibendum nec. Praesent justo quam, sodales eu dui vel, iaculis feugiat nunc.

Pellentesque faucibus orci at lorem viverra, id venenatis justo pretium. Nullam congue, arcu a molestie bibendum, sem orci lacinia dolor, ut congue dolor justo a odio.

post content right img

Duis odio neque, congue ut iaculis nec, pretium vitae libero. Cras eros ipsum, eleifend rhoncus quam at, euismod sollicitudin erat.

Fusce imperdiet, neque ut sodales dignissim, nulla dui. Nam vel tortor orci.

Post author namePost author url
Post author biographical information.
Subscribe to Medical Device News Magazine

New 12-month Results from RHINTRAC Randomized Controlled Trial Demonstrate Durable Safety & Efficacy of Aerin Medical’s RhinAer for Treatment of Chronic Rhinitis

These results for the trial’s active treatment arm showed that chronic rhinitis symptoms continued to improve through 12 months after treatment with RhinAer.

Two-part Study Finds That Remote Patient Monitoring with Masimo SafetyNet Reduced Length of Hospital Stay for COVID-19 Patients

Masimo SafetyNet is a remote patient management and telehealth solution, that uses tetherless Masimo Radius PPG™ SET® pulse oximetry and a smartphone app to seamlessly transmit continuous home-based patient monitoring data to hospital clinicians.

Nevro Corp Newly Released Clinical Data

D. Keith Grossman, Chairman, CEO and President of Nevro said, "In addition to the strong clinical efficacy for HFX Therapy that has already been shown in our landmark SENZA-PDN trial, these results demonstrate improvement in several important health-related quality of life metrics in patients with PDN."